Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2016

View Archived Issues

ZIOPHARM plans phase I study of CD33 CAR T-cell therapy

MJFF, van Andel Research and Cure Parkinson's Trust to study nilotinib in Parkinson's disease

IntelGenx starts phase I trial of montelukast for the treatment of neurodegenerative diseases

Oncodesign launches phase 0/I trial for ODS-2004436 radiotracer

Mutations in TRMT10C identified as a cause of mitochondrial disease

Aptinyx starts dosing in phase I trial for NYX-2925

Merck & Co. patents BTK inhibitors

OncoArendi Therapeutics describes arginase inhibitors

King's College London discloses retinoid RARbeta receptor agonists

Revlimid approved in Europe for relapsed or refractory MCL

Hitgen reports HDAC inhibitors

NovoBiotic Pharmaceuticals receives grant from NIAID to advance teixobactin program

Dethree Res, J-Pharma and Nippon Chemiphar present URAT1 inhibitors

Update on U.S. regulatory filing for Raxone in Duchenne muscular dystrophy

Juno Therapeutics acquires RedoxTherapies

Boehringer Ingelheim announces collaboration with the University of Dundee

Three organizations merge to form Lupus Research Alliance

ArmaGen presents data on AGT-182 for Hunter syndrome

GSK exercises option under respiratory disease collaboration with Five Prime

Plex Pharmaceuticals obtains funding to develop compounds for Parkinson's disease

NTRK2 shows promise as a therapeutic target for astrocytoma

Disruption of TRIP8b-HCN interaction may induce antidepressant-like behavior

Tyrosine kinase inhibitor shows promise in Parkinson's disease patients

FDA advisory committee recommends approval of biosimilar etanercept

New panel shows promise for infection diagnosis

An RYR1 mutation is associated with bleeding abnormalities

NIH expands investment to advance basic medical research toward HIV cure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...